Abcepta manufactured the first research grade antibodies against coronavirus proteins in 2003.
Coronavirus-related product lines include:
- 30+ antibodies targeting multiple coronavirus proteins
- 950+ peptides from SARS and SARS-2 coronavirus proteins
- 2500+ host protein specific antibodies covering the viral life cycle
Abcepta continues to operate and ship worldwide, assuring your access to trusted reagents for urgent high-impact research during the COVID-19 pandemic.
Viral Entry and Processes
SARS CoV-2 PPIs
Cytokines and Inflammation